Table 4 Metformin plus saxagliptin vs. metformin plus sulfonylurea: Events and costs
From: Treatment of type 2 diabetes with saxagliptin: a pharmacoeconomic evaluation in Argentina
|  | MET + SU | MET + SAXA | Difference | |||
|---|---|---|---|---|---|---|
| Â | Events | Cost | Events | Cost | Events | Cost |
Macrovascular | Â | Â | Â | Â | Â | Â |
IHD | 99.2 | 193,759 | 99.0 | 193,285 | −0.2 | −474 |
MI | 270.4 | 518,858 | 268.1 | 515,859 | −2.3 | −3,000 |
CHF | 81.4 | 62,861 | 76.2 | 58,716 | −5.2 | −4,144 |
Stroke | 90.6 | 111,876 | 89.9 | 111,084 | −0.7 | −792 |
Microvascular | Â | Â | Â | Â | Â | Â |
Blindness | 60.5 | 36,879 | 60.6 | 36,503 | 0.2 | −376 |
Nephropathy | 13.0 | 420,397 | 12.9 | 410,562 | −0.1 | −9,834 |
Amputation | 24.4 | 20,407 | 24.4 | 19,965 | −0.1 | −442 |
Hypoglycemia | 1,179 | 128,719 | 1,032 | 108,438 | −147 | −20,281 |
Treatment | - | 9,201,014 | - | 10,873,266 | - | 1,672,252 |
Total | Â | 10,694,769 | Â | 12,327,677 | Â | 1,632,909 |